Mineralys Therapeutics announced positive Phase 2 trial results for lorundrostat, an aldosterone synthase inhibitor, in patients with uncontrolled hypertension and chronic kidney disease (CKD). The drug significantly reduced systolic blood pressure by 7.5 mmHg and lowered urinary albumin and protein levels, markers of kidney damage, after four weeks of treatment. These findings suggest lorundrostat may help manage difficult-to-treat hypertension and protect kidney function in CKD patients. Further long-term studies are planned to confirm these benefits.
The story on Mineralys Therapeutics' Phase 2 trial results for lorundrostat provides context for readers following health-sector stocks. As of Oct 28, 2026 17:41 WIB, 42 of 150 priced health-sector US stocks on Pluang rose while 94 fell. Notable movers include Boston Scientific Corporation (BSX) at USD 44.03 with a 2.27% decline and Twist Bioscience Corp (TWST) at USD 163.00 with a 1.97% gain.
Arcutis Biotherapeutics has appointed Dr. Rob Scott, a seasoned pharmaceutical executive with over 40 years of experience, to its Board of Directors. Dr. Scott's expertise in developing and securing approvals for innovative medicines, including derma...
Air Canada and CAE announced the opening of applications on November 1, 2026, for the 2027 Commandante-Judy-Cameron scholarships. These scholarships support up to eight Canadian women pursuing professional pilot or aircraft maintenance technician tra...
The Legacy Lab by Team One released its 2026 Legacy Makers 100 list, identifying brands consumers trust to have their best interests at heart and remain relevant long-term. St. Jude Children's Research Hospital topped the list for the second year. Th...
Circuit Mind has introduced AVE (Agentic Verification Engine), an AI-powered application that verifies printed circuit board (PCB) schematics against datasheets and internal design rules to catch errors early and avoid expensive respins. AVE compleme...
Grabar Law Office is investigating claims against officers and directors of Erasca, Planet Fitness, PROCEPT BioRobotics, and The Simply Good Foods Company for alleged breaches of fiduciary duties. The investigations focus on misleading statements and...
